Marshall Wace, LLP Ngm Biopharmaceuticals Inc Transaction History

Marshall Wace, LLP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$17.26 - $22.02 $1.48 Million - $1.89 Million	-86,027 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$20.15 - $26.19 $1.73 Million - $2.25 Million	86,027 New	86,027 $1.81 Million
Q2 2021 Aug 13, 2021	SELL	$15.06 - $30.03 $686,389 - $1.37 Million	-45,577 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$24.99 - $31.93 $1.14 Million - $1.46 Million	45,577 New	45,577 $1.33 Million
Q2 2020 Aug 13, 2020	SELL	$11.97 - $23.47 $2.74 Million - $5.36 Million	-228,551 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$10.0 - $19.51 $2.29 Million - $4.46 Million	228,551 New	228,551 $2.82 Million

2.6M

300

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.